Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.

JAMA Oncol. 2018 Dec 27. doi: 10.1001/jamaoncol.2018.5801. [Epub ahead of print]

PMID:
30589920
2.

Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.

Cohen R, Hain E, Buhard O, Guilloux A, Bardier A, Kaci R, Bertheau P, Renaud F, Bibeau F, Fléjou JF, André T, Svrcek M, Duval A.

JAMA Oncol. 2018 Nov 15. doi: 10.1001/jamaoncol.2018.4942. [Epub ahead of print]

PMID:
30452494
3.

The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.

Sorscher S.

Oncologist. 2018 Nov;23(11):1266-1268. doi: 10.1634/theoncologist.2017-0681. Epub 2018 Jun 4.

PMID:
29866945
4.

Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.

Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim HR, Sadowska J, Berger MF, Delair DF, Shia J, Stadler Z, Klimstra DS, Ladanyi M, Zehir A, Hechtman JF.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00084. Epub 2017 Oct 3.

5.

Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.

Roncati L.

Acta Dermatovenerol Croat. 2018 Dec;26(4):341-343.

PMID:
30665488
6.

The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.

Feng YC, Ji WL, Yue N, Huang YC, Ma XM.

Cancer Manag Res. 2018 Jan 18;10:105-113. doi: 10.2147/CMAR.S152232. eCollection 2018.

7.

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

Cohen R, Buhard O, Cervera P, Hain E, Dumont S, Bardier A, Bachet JB, Gornet JM, Lopez-Trabada D, Dumont S, Kaci R, Bertheau P, Renaud F, Bibeau F, Parc Y, Vernerey D, Duval A, Svrcek M, André T.

Eur J Cancer. 2017 Nov;86:266-274. doi: 10.1016/j.ejca.2017.09.022. Epub 2017 Oct 19.

PMID:
29055842
8.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4.

9.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T.

Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum in: Lancet Oncol. 2017 Sep;18(9):e510.

10.

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.

Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ.

Mol Cancer Res. 2018 May;16(5):805-812. doi: 10.1158/1541-7786.MCR-17-0735. Epub 2018 Mar 9.

PMID:
29523759
11.

Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Lupinacci RM, Goloudina A, Buhard O, Bachet JB, Maréchal R, Demetter P, Cros J, Bardier-Dupas A, Collura A, Cervera P, Scriva A, Dumont S, Hammel P, Sauvanet A, Louvet C, Delpéro JR, Paye F, Vaillant JC, André T, Closset J, Emile JF, Van Laethem JL, Jonchère V, Abd Alsamad I, Antoine M, Rodenas A, Fléjou JF, Dusetti N, Iovanna J, Duval A, Svrcek M.

Gastroenterology. 2018 Mar;154(4):1061-1065. doi: 10.1053/j.gastro.2017.11.009. Epub 2017 Nov 20.

PMID:
29158190
12.

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.

Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R.

JAMA Oncol. 2018 Sep 1;4(9):1237-1244. doi: 10.1001/jamaoncol.2018.1701.

13.

DNA mismatch repair in cancer.

Baretti M, Le DT.

Pharmacol Ther. 2018 Sep;189:45-62. doi: 10.1016/j.pharmthera.2018.04.004. Epub 2018 Apr 15. Review.

PMID:
29669262
14.
15.

Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.

Middha S, Yaeger R, Shia J, Stadler ZK, King S, Guercio S, Paroder V, Bates DDB, Rana S, Diaz LA Jr, Saltz L, Segal N, Ladanyi M, Zehir A, Hechtman JF.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00321. Epub 2019 Mar 4.

PMID:
31008436
16.

Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.

Czink E, Kloor M, Goeppert B, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, Doeberitz MVK, Jäger D, Springfeld C.

Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a001974. doi: 10.1101/mcs.a001974. Print 2017 Sep.

17.
18.

Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.

Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J.

Cancer Med. 2018 Mar;7(3):746-756. doi: 10.1002/cam4.1372. Epub 2018 Feb 13. Erratum in: Cancer Med. 2018 Jun;7(6):2792.

19.

Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.

Le Flahec G, Badic B, Guibourg B, Doucet L, Bail JP, Marcorelles P, Schick U, Uguen A.

Hum Pathol. 2018 Feb;72:135-143. doi: 10.1016/j.humpath.2017.09.019. Epub 2017 Dec 5.

PMID:
29208565
20.

Precision medicine becomes reality-tumor type-agnostic therapy.

Yan L, Zhang W.

Cancer Commun (Lond). 2018 Mar 31;38(1):6. doi: 10.1186/s40880-018-0274-3. Review.

Supplemental Content

Support Center